Pomerantz Law Firm Investigates Cellectis S.A. Following Strategic Pivot and Stock Decline
Pomerantz LLP has launched an investigation into Cellectis S.A. (CLLS) to determine if the company or its executives engaged in securities fraud or unlawful business practices. The probe follows a significant strategic shift announced by the company on September 14, 2026, where Cellectis decided to prioritize in vivo gene editing therapies over its existing CAR-T cell therapy programs. During this announcement, Cellectis confirmed it would discontinue development of lasme-cel and eti-cel due to limited cash resources and financing constraints. The market reacted sharply to the news, with Cellectis ADR prices plummeting 40.97% to close at $1.83 on the day of the announcement.
Tickers: $CLLS
Topics: biotechnology class action lawsuit gene editing securities fraud investigation stock price drop